Growth-Hormone Response to Bromocriptine in Parkinsonism

Shaw, Kenneth; Lees, Andrew J.; Hayes, Sheila; Ross, E. J.; Stern, Gerald; Thompson, B. D.

doi:10.1016/s0140-6736(76)91298-8

Cited by 10 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data are consistent with those reported by Shaw et al (1976) who used larger doses of drugs in their parkinsonian patients. In this respect, the effect of bromocryptine differs from the one observed with levo dopa.…”

Section: Discussionsupporting

confidence: 91%

Changes in Pituitary Hormones Serum Levels in Bromocryptine-Treated Parkinsonian Patients

Polleri¹,

Carolei²,

Rolandi³

et al. 1977

Neuropsychobiology

View full text Add to dashboard Cite

In the course of a clinical trial with 2α-bromoergocryptine in Parkinson’s disease, the serum levels of several pituitary hormones have been studied in the assumption that the drug active on nigro-striatal dopaminergic system might also interfere with hypothalamus-protuberantial neurotransmission, and have effects on the function of the pituitary. No changes in serum levels of FSH, LH, STH and TSH were detected for every dose of the drug employed. Only prolactin serum levels diminished since the beginning of the treatment, the decrease being significant (p < 0.05 and p < 0.01). This effect on prolactin does not change in the dose range considered. Clinical improvement was observed for doses of drugs above 15 mg/day, whereas the effect on prolactin secretion occurred with the dose of 7.5 mg/day.

show abstract

Section: Discussionsupporting

confidence: 91%

Changes in Pituitary Hormones Serum Levels in Bromocryptine-Treated Parkinsonian Patients

Polleri¹,

Carolei²,

Rolandi³

et al. 1977

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…During treatment of parkinsonian patients with bromocriptine, the following hormonal effects have been noted: suppression of plasma prolactin (99–101); nonsignificant suppression of the thyroid‐stimulating hormone response to thyroid‐releasing hormone stimulation (102); and no changes in plasma growth hormone (99, 101, 103), follicle‐stimulating hormone, luteinizing hormone, or thyrotropin (99, 100). The degree of suppression of prolactin does not correlate with the degree of improvement in parkinsonism (100, 101).…”

Section: Adverse Reactionsmentioning

confidence: 99%

Bromocriptine and Its Use in Parkinsonism

Hoehn

1981

J American Geriatrics Society

View full text Add to dashboard Cite

Bromocriptine is a potent dopamine agonist which directly stimulates dopamine receptors. In the corpus striatum, this action results in alleviation of many of the signs and symptoms of parkinsonism. The effectiveness of bromocriptine may persist for at least one to two years; results of more prolonged treatment are not available. Adverse reactions are common and often severe, but safety in dosages up to 100 mg daily for one to two years has been adequately established. Bromocriptine is qualitatively and quantitatively similar to levodopa in both beneficial and adverse effect. However, because of variations in individual response, bromocriptine sometimes ameliorates the problems of prolonged levodopa therapy, i.e., declining efficacy, fluctuations in therapeutic response, and the development of disabling abnormal involuntary movements, Thus bromocriptine is a valuable adjunct in the treatment of parkinsonism.

show abstract